GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (FRA:W2J) » Definitions » Purchase Of Investment

CARISMA Therapeutics (FRA:W2J) Purchase Of Investment : €0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics Purchase Of Investment?

CARISMA Therapeutics's purchase of investment for the three months ended in Mar. 2025 was €0.00 Mil. It means CARISMA Therapeutics spent €0.00 Mil on purchasing investments. CARISMA Therapeutics's purchase of investment for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Dec. 2024 ), CARISMA Therapeutics spent the same money on purchasing investments in Mar. 2025 (€0.00 Mil).


CARISMA Therapeutics Purchase Of Investment Historical Data

The historical data trend for CARISMA Therapeutics's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics Purchase Of Investment Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Purchase Of Investment
- - -85.81 -31.60 -

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CARISMA Therapeutics Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CARISMA Therapeutics Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


CARISMA Therapeutics Business Description

Traded in Other Exchanges
Address
3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics Headlines

No Headlines